Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
Abstract
The long-term outcomes of treatment with new selective antipsychotic for patients with schizophrenia have been discussed. Using the example of patients treated with “Xeplion” for secondary prevention of worsening symptoms of the disorder and changing in patient social functionality are in the focus. Especial attention paid on safety and efficacy of the treatment. Addressed to psychiatrists working in health services and researchers.
References
1. Гурович И.Я., Шмуклер А.Б., Сторажакова Я.А. Психосоциальная терапия и психосоциальная реабилитация в психиатрии. - 2004.
2. Nuss P., Tessier C. Curr. - Med Res Opin. - 2010. - Vol. 26, No. 4. - Р. 787-801.
3. Залуцкая Н.М. Восстановительная модель терапии шизофрении: выполнима ли в современных условиях?-Журнал неврологии и психиатрии имени Корсакова С.С. - 2015. - Т. 115. - С. 11.
4. Norman R.M., Malla AX., Cortese L, et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. - Am J. Psychiatry. -1999. - Vol. 156. - P. 400-513.
5. Awad A.G., Voruganti L.N., Heslegrave RJ. A conceptual model of quality of life in schizo-phrenia: description and preliminary clinical validation. - Qual Life Res. - 1997. - Vol. 6. - P.21-26.
6. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. - Pharmacoeconomics. - 2000. - Vol. 18. - P. 106-124.
7. Hellewell J.S. Patients’ subjective experiences of antipsychotics: clinical relevance. - CNS Drugs. - 2002. - Vol. 16. - P. 457-471.
8. Voruganti L., Cortese L., Oyewumi L., et al. Comparative evaluation of conventional and novel an tipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. - Schizophr Res. - 2000. - Vol. 43. - P. 135-145.
9. Mortimer A.M., Al-Agib A.O. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. - Int J. Soc Psychiatry. - 2007. - Vol. 53. - P. 99-107.
10. Ritsner M., Gibel A., Perelroyzen G., et al. Quality of life outcomes of risperidone, olan-zapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. - J. Clin Psychopharmacol. - 2004. - Vol. 24. - P. 582-591.
11. Divanon F., Delamillieure P., Lehaguez A., et al. [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study]. - Encephale. - 2006. - Vol. 32. - P. 459465.
12. Davis J.M., Chen N., Glick I.D. A Meta-analysis of the Efficacy of Second-Generation Antipsichotics, Arch. - Gen.Psichiatry - 2003. - Vol. 60. - P. 553564.
13. Войтенко Р.М. Социальная психиатрия с основами медико-социальной экспертизы и реабилиталогии. - СПб. - 2011.
Review
For citations:
Grigorieva E.V. Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2017;(1):59-62. (In Russ.)
Views:
494
Email this article 